Format

Send to

Choose Destination
PLoS One. 2015 Feb 25;10(2):e0116755. doi: 10.1371/journal.pone.0116755. eCollection 2015.

Multifactorial analysis of conditional reprogramming of human keratinocytes.

Author information

1
Department of Pathology, Georgetown University, Washington, DC, 20007, United States of America.
2
Department of Oncology, Georgetown University, Washington, DC, 20007, United States of America.
3
Department of Oncology, Georgetown University, Washington, DC, 20007, United States of America; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20007, United States of America.
4
Department of Molecular and Microbiology, George Mason University, Manassas, Virginia, 20110, United States of America.
5
Department of Pathology, Georgetown University, Washington, DC, 20007, United States of America; Department of Oncology, Georgetown University, Washington, DC, 20007, United States of America; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20007, United States of America.

Abstract

Co-culture of human primary epithelial cells with irradiated 3T3 fibroblast feeder cells (J2 cells) and the Rho kinase inhibitor Y-27632 (Y) allows for the unrestricted growth of cells of epithelial origin by the process termed conditional reprogramming. To better understand the nature of the signaling processes associated with conditionally reprogrammed cells, the effect of the two critical components of the co-culture conditions, J2 cells and Y, on the growth of human foreskin keratinocytes (HFKs) was evaluated by gene expression profiling, reverse-phase protein arrays and siRNA screening. J2 cells and Y acted cooperatively to down-regulate differentiation, and upregulate proliferation and cell adhesion, including increased pT308Akt and pERK, and reduced TGF-β pathway signaling. These findings establish a mechanistic basis for the unlimited growth potential of human epithelial cells that will be invaluable to assess the effect of genetic changes in pathologic tissues and their response to therapeutic agents.

PMID:
25714835
PMCID:
PMC4340869
DOI:
10.1371/journal.pone.0116755
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center